Retinal oximetry does not predict 12‐month visual outcome after anti‐VEGF treatment for central retinal vein occlusion: A multicentre study

2021 ◽  
Author(s):  
Signe Krejberg Jeppesen ◽  
Martin Sín ◽  
Sveinn Hakon Hardarson ◽  
Toke Bek
Keyword(s):  
Multicentre Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Visual Outcome ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein ◽  
Retinal Oximetry

Predictors of Short-Term Visual Outcome after Anti-VEGF Therapy of Macular Edema due to Central Retinal Vein Occlusion

2011 ◽  
Vol 52 (6) ◽  
pp. 3334 ◽  
Author(s):  
Ute E. K. Wolf-Schnurrbusch ◽  
Ramzi Ghanem ◽  
Simon P. Rothenbuehler ◽  
Volker Enzmann ◽  
Carsten Framme ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Visual Outcome ◽  
Short Term ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

scholarly journals The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Christina L. Ryu ◽  
Adrian Elfersy ◽  
Uday Desai ◽  
Thomas Hessburg ◽  
Paul Edwards ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Significant Risk ◽  
Case Series ◽  
Neovascular Glaucoma ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes.Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion

2020 ◽  
Vol 28 (1) ◽  
pp. 70-76
Author(s):  
H. D. Jeffry Hogg ◽  
S. James Talks ◽  
Mark Pearce ◽  
Sandro Di Simplicio
Keyword(s):  
Retinal Vein Occlusion ◽  
Real World ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

scholarly journals Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicentre study

2016 ◽  
Vol 95 (3) ◽  
pp. e245-e246 ◽  
Author(s):  
Gesine B. Szurman ◽  
Kai Januschowski ◽  
Peter Szurman ◽  
Nicolas Feltgen ◽  
Bernhard Spitzer ◽  
...  
Keyword(s):  
Multicentre Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Vein Occlusion ◽  
Injection Scheme ◽  
Central Retinal Vein

scholarly journals Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion

2017 ◽  
Vol Volume 11 ◽  
pp. 331-336 ◽  
Author(s):  
Kaveh Abri Aghdam ◽  
Lukas Reznicek ◽  
Mostafa Soltan Sanjari ◽  
Annemarie Klingenstein ◽  
Marcus Kernt ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

scholarly journals Changes in peripapillary and subfoveal choroidal thickness in patients with central retinal vein occlusion

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255182
Author(s):  
Hae Min Kang ◽  
Jeong Hoon Choi ◽  
Hyoung Jun Koh ◽  
Sung Chul Lee
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Choroidal Thickness ◽  
Visual Outcome ◽  
Subfoveal Choroidal Thickness ◽  
Vein Occlusion ◽  
Absolute Reduction ◽  
Treatment Naïve ◽  
Central Retinal Vein

Purpose We sought to evaluate changes of mean peripapillary choroidal thickness (PCT) and subfoveal choroidal thickness (SFCT) over 12 months in patients with unilateral central retinal vein occlusion (CRVO). Methods Our retrospective, observational study included 19 patients with treatment-naïve, unilateral CRVO who completed at least 12 months of follow-up period. Mean PCT and mean SFCT in CRVO-affected eyes and unaffected contralateral eyes were measured at each follow-up visit, and then compared. Differences between baseline and 12 months (ΔSFCT and ΔPCT) and percentage changes (ΔSFCT or ΔPCT/baseline×100%) were determined. We also investigated the predictive factors for visual outcome in the CRVO-affected eyes. Results In the CRVO-affected eyes, mean PCT was 146.7±41.9 μm at baseline, and 106.5±24.2 μm at 12 months (P < 0.001). Mean PCT of the contralateral eyes was 129.8±42.6 μm at baseline and 124.6±39.7 μm at 12 months (P = 0.089). Mean SFCT of CRVO-affected eyes was 225.8±77.9 μm at baseline, and 199.4±66.6 μm at 12 months (P = 0.009). Mean SFCT of the contralateral eyes was 218.4±83.0 μm at baseline, and 208.4±78.1 μm at 12 months (P = 0.089). Δ PCT was -41.6±25.3 μm in the CRVO-affected eyes, and -5.2±5.8 μm in the contralateral eyes (P<0.001). % PCT was -24.9±14.0% in the CRVO-affected eyes, and -4.0±0.4% in the contralateral eyes (P = 0.001). Δ SFCT was -26.4±24.6 μm in the CRVO-affected eyes, and -9.5±16.7μm in the contralateral eyes (P = 0.016). % SFCT was -10.4±9.8% in the CRVO-affected eyes, and -3.4±6.4% in the contralateral eyes (P = 0.015). Among the various factors, BCVA at baseline (β = 0.797, P = 0.001) and % SFCT (β = 0.712, P = 0.001) were significantly associated with visual outcome at 12 months in the CRVO-affected eyes. Conclusion Both peripapillary and subfoveal choroidal thickness reduced significantly over 12 months in the CRVO-affected eyes, but not in the contralateral eyes. In addition, the absolute reduction amount and reduction ratio of PCT and SFCT were significantly greater in the CRVO-affected eyes than the contralateral eyes.

Sign in / Sign up

Export Citation Format

Share Document